Vertex Pharmaceuticals VRTX Indefinite- lived intangible impairment

Indefinite- lived intangible impairment at other companies

AbbVieABBV

——

Other financials

Income statement

See full

Revenue$3.0B+7.8%

Gross profit$2.6B+7.8%

Operating income$1.1B+80.6%

Net income$1.0B+59.6%

EPS (diluted)$4.02+61.4%

Balance sheet

See full

Cash & equivalents$5.5B+17.5%

Total debt$2.0B+20.5%

Total equity$19.4B+17.4%

Total assets$26.5B+15.8%

Cash flow

See full

Operating cash flow$1.4B+74.4%

CapEx$133.4M+228%

Free cash flow$1.3B+66.4%

Valuation

See full

Market cap$126.07B+17.7%

Enterprise value$122.55B+18.2%

P/E29.1×—

P/S10.3×+0.9×

Profitability

See full

Gross margin86.2%+0.2pp

Operating margin38.3%—

Net margin35.5%—

FCF margin30.4%+20.2pp

Returns & leverage

See full

Return on equity24.2%—

Debt / equity0.1×0.0×

Current ratio3×+0.4×

Where this comes from

Reported directly by Vertex Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:IntangibleAssetsGrossExcludingGoodwill.

The official record: Vertex Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vertex Pharmaceuticals's indefinite- lived intangible impairment.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Vertex Pharmaceuticals's indefinite- lived intangible impairment?: Vertex Pharmaceuticals (VRTX) reported indefinite- lived intangible impairment of $470.3M in Q1 2026.
How has Vertex Pharmaceuticals's indefinite- lived intangible impairment changed year-over-year?: Vertex Pharmaceuticals's indefinite- lived intangible impairment decreased by 0.0% year-over-year, from $470.3M to $470.3M.